Q2 2022 ImpediMed Ltd Activities Report Call Transcript
Thank you for standing by, and welcome to the ImpediMed Limited Quarterly Results and Investor Conference Call. (Operator Instructions)
I would now like to hand the conference over to Mr. Richard Carreon, Managing Director and CEO. Please go ahead.
Thanks, Kelly. Welcome, everyone, and thank you for joining us today. We're hosting this conference call to discuss our 4C for the financial quarter ending 31 December 2021. Joining us on the call today is Tim Cruickshank, our Chief Financial Officer; and Mike Bassett, our Senior Vice President of Corporate and Strategic Development.
I'll be referencing the 4C and speaking from the quarterly activity report we lodged this morning Australian time. This presentation is a summary of the more detailed 4C. After our remarks, we'll be taking questions.
Let me first start off by providing an update on the publication of the PREVENT trial. The principal investigator, Dr. Sheila Ridner, received notification late last
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |